Conor Targeting Year-End IDE Submission For Paclitaxel-Eluting Stent
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is preparing to submit an investigational device exemption for a pivotal trial supporting a premarket application for its CoStar cobalt chromium stent. However, a market launch could be hindered by intellectual property issues over use of the drug.